Eletriptan
Relpax · Relpax free aMine · UK-116044 · ELETRIPTAN · (R)-Eletriptan · Unii-22qoo9B8ki · Eletriptan Free Base · Eletriptan USP/EP/BP
식별자 및 물리적 특성
| CAS No. | 143322-58-1 |
|---|---|
| 분자식 | C22H26N2O2S |
| 평균 분자량 | 382.5 g/mol |
| 단동위원소 질량 | 382.17149907 g/mol |
| SMILES | CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12 |
| InChIKey | PWVXXGRKLHYWKM-LJQANCHMSA-N |
| PubChem CID | 77993 |
| ChEMBL | CHEMBL1510 |
| ChEBI | CHEBI:50922 |
| EC No. | 640-088-3 |
| DTXSID | DTXSID9046861 |
화학 및 물리적 성질
| XLogP | 4.1 |
|---|---|
| 극성 표면적 | 61.6 |
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 3 |
| 회전 가능 결합 수 | 6 |
| 무거운 원자 수 | 27 |
| 형식 전하 | 0 |
| 복잡도 | 582 |
| 의약품 | Pharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 3.9 |
| 용해도 | Readily soluble as hydrobromide formulation1.18e-03 g/LDMSO(약간 용해됨), 메탄올(약간 용해됨) |
| Human Drugs | Breast FeedingLactationMilk, HumanSerotonin Receptor AgonistsSerotonin 5-HT1 Receptor AgonistsTriptansVasoconstrictor AgentsPharmaceuticals |
| Physical Description | Solid |
| Collision Cross Section | 189.45 Ų [M+K]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]186.1 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| 녹는점 | 168-170C |
| 끓는 점 | 613.4±55.0 °C(Predicted) |
| 밀도 | 1.235±0.06 g/cm3(Predicted) |
| 저장 조건 | Sealed in dry,Room Temperature |
| 물리적 상태 | 고체 |
| pKa(산도 계수) | 17.14±0.30(Predicted) |
| 색상 | 연한 노란색에서 진한 노란색까지 |
| 안정성 | 흡습성 |
| InChI | InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1 |
| InChIKey | PWVXXGRKLHYWKM-LJQANCHMSA-N |
| SMILES | N1C2=C(C=C(CCS(C3=CC=CC=C3)(=O)=O)C=C2)C(C[C@H]2CCCN2C)=C1 |
화학적 성질
Yellow Foam
안전 및 규제
| GHS 분류 | DangerH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P264+P265, P270, P273, P280, P301+P317, P305+P354+P338, P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 29 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| 유해 작용 | Adverse events reported from eletriptan use are mostly mild, moderate, and transient. Although eletriptan is associated with nausea, dizziness, drowsiness, and coronary vasoconstriction, the most common adverse effects include a group of sensations referred to as "triptan sensations," including paresthesia, flushing, tingling, chest tightness, and neck pain. Additional effects, such as palpitations, headaches, chills, pain, hypertonia, hypoesthesia, diaphoresis, abdominal pain, including cramps, discomfort, and pressure, xerostomia, dysphagia, dyspepsia, pharyngitis, back pain, and generalized weakness, have been reported, albeit at a much lower incidence ranging from 1% to 7%. |
| 독성 요약 | Signs and Symptoms of Overdose |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)eletriptanDILI NegativeOralDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 신호 어 | Danger |
| 유해·위험 문구 | 암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302 |
용도
용도
Eletriptan is a selective serotonin 5-HT1B and 5-HT1D receptor agonist and used to treat migraines (1,2,3).
일반 설명
Eletriptan, introduced into the market in 2002, is the newesttriptan with highest affinity for 5-HT1B, 5-HT1D, and 5-HT1Freceptors. It is one of the most lipophilic triptans marketedto date and is well tolerated and safe across its dosing rangeof 20 to 80 mg. However, it is metabolized primarily(>90%) by CYP3A4 isozyme to its active metabolite, theN-desmethyleletriptan, which accounts for approximately10% to 20% of the plasma concentration of that observedfor parent drug. Thus, coadministration of eletriptan withpotent CYP3A4 inhibitors such as ketoconazole, itraconazole,nefazodone, troleandomycin, clarithromycin, ritonavir,and nelfinavir may require dose reduction and closer monitoringfor CNS side effects. Furthermore, becauseeletriptan and its active metabolite, N-desmethyleletriptan,are also substrates for the P-glycoprotein efflux pumps thatare responsible for their removal from the brain, coadministrationof eletriptan with a known P-glycoprotein inhibitorand/or inducer such as digoxin, diltiazem, verapamil, or St.John’s Worth would result in higher brain levels of its activemetabolite, and thus a higher rate of the CNS side effectsreported for this drug.